Skip to main content
Dryad

Physical activity is associated with exercise capacity among patients undergoing chemotherapy: a pilot randomized controlled trial

Data files

Aug 14, 2025 version files 4.53 KB

Click names to download individual files

Abstract

Exercise intolerance is common among cancer patients undergoing active treatments.\
We conducted a pilot study in patients receiving potentially cardiotoxic therapies to investigate the\
impact of participation in a 6-month physical activity intervention (PAI) versus a healthy lifestyle\
education control intervention (HLI) on accelerometer-derived measures of PA (steps/day or minutes\
of moderate to vigorous PA [MVPA]/week) and whether these measures were associated with\
submaximal exercise capacity (6-minute walk distance [6MWD]). Participants with breast\
cancer or lymphoma (n=33) were randomized (2:1) into PAI or HLI groups. Exercise training was\
patient-centered, tailored to treatment and functional status. Objective assessments of PA (steps/day,\
MVPA/week), and submaximal exercise capacity (6MWD) were completed at baseline, 3-, and 6-\
months. Separate linear mixed-effects regression models examined changes in 6MWD, controlling\
for baseline values, a treatment group x time interaction, steps/day, or MVPA. At baseline,\
27 participants in the PAI (n=20) and HLI (n=7) groups who completed baseline and at least 1 follow\
up visit, had a mean age of 53 ±17 vs 57 ±13 years, took on average 8,330 ±2520 vs 7800 ±3830\
steps/day, did an average of 133 ±44 vs 109 ±87 minutes of MVPA/week, and had a mean 6MWD of\
496 ±94 vs 440 ±18 meters, respectively. Models adjusted for baseline values did not show any\
difference in 6MWD by intervention group or time. Further, no significant differences in steps/day or\
MVPA mins/week were found between groups over time. A post-hoc correlation analysis did find\
significant associations between both steps/day (r=0.51, p=.04) and MVPA mins/week (r=0.48,\
p≤.05) and 6MWD at 6-months. Baseline data indicate that, on average, our study\
sample was close to meeting the PA guidelines. Unexpectedly, both groups maintained their activity\
levels up to 3- and 6-months. Submaximal exercise capacity (6MWD) was also maintained (with a\
clinically meaningful but not statistically significant relative benefit in the PAI) suggesting higher PA\
levels may associate with reduced exercise intolerance after anthracycline therapy.